Kidney Week

Abstract: SA-PO0830

Temporal Associations Between COVID-19 Disease (C19D), Vaccination (C19V), and IgAN

Session Information

• Glomerular Management: Real-World Lessons and Emerging Therapies
  November 08, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Iftikhar, Nimra, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Nimra Iftikhar, MD

• Singh, Namita, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Namita Singh, MD, MBBS, FASN

• Garcia, Pablo, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Pablo Garcia, MD, MS, FASN

• Liu, Song, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Song Liu, MD

• de Leoz, Josephine B., The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Josephine B. de Leoz, MD

• Mir, Hamza, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Hamza Mir, MSc, MSW

• Argyropoulos, Christos, University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States

Christos Argyropoulos, MD, MS, MSc, PhD, FASN

Background

The pathophysiology of IgAN involves the deposition of circulating immune complexes & the activation of the complement system. SARS-CoV-2 infection activates similar pathways, while case reports link C19V to IgA apperance & relapse. There is limited information about the association of IgAN and C19D.C19V at the population level

Methods

We included all patients who had a C19 test and the IgAN ICD10 code (N02) between 3/1/20-3/31/24 in any US institute in the TrinetX database. C19V, & C19D were assessed by +ve results in respiratory panel testing (RPT) and the vaccination records. We used a Self Controlled Case Series (BMJ 2016;354:i4515) to analyze the temporal risk of repeat C19D and C19V on the appearance of a N02 code.

Results

Out of 14M patients with RPT, 605 met the inclusion criteria (figure). Age was 49.4 ± 17, 47% of patients were female and 69% were white. There was no temporal association between C19V and the incidence of a new N02 code. However, there was an increased incidence of N02 between 3-6 months after a C19D with reduction in the risk afterwards (Table).

Conclusion

In this exploration C19D, but not C19V was associated with a higher temporal risk of IgAN. Whether this will translate to a higher burden of disease is unknown. Future studies should determine the need for surveillance for IgAN post C19D. Limitations include undercoding of IgAN and lack of the biopsy reports to corroborate the ICD10 code.

Time Dependent RR (95% CI and p-values) of a new IgAN ICD10 code relative to C19D and C19V

Reference : period before any C19 RPT, C19D and C19V

Funding

• Other NIH Support

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025hrzvf9wv